Announced public offer for all shares of US-based Respironics

Guiding principles for acquisitions

 

Growth opportunities in our high margin, more predictable businesses

No or time-limited margin dilution

Quality of management

Clear commercial, clinical, and technology synergies

Complementary position

Strong market position

Integration strategy part of acquisition decision

Walk-away price set based on EVA analysis

A good alliance is an alternative to acquisition

Announced public offer for all shares of US-based Respironics

Conference call

 

On Friday December 21, 2007, Royal Philips held a conference call at 10:00AM CET (Dutch time) on the occasion of the announcement of a public offer for all shares of US-based Respironics.

 

This conference call was hosted by Gerard Kleisterlee, President and CEO, Pierre-Jean Sivignon, Chief Financial Officer, and Steve Rusckowski, Chief Executive Officer of Philips Healthcare.

 

Below please find the transcript of this call and the presentation slides.